Clinical Trial

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this phase 2 research study is to determine whether a combination of chemotherapy drugs plus radiation therapy, given before surgery in resectable pancreactic cancer, can help to increase the chances of surgeons achieving and R0 resection. The chemotherapy drugs used are gemcitabine and nab-paclitaxel. These drugs are both approved by the FDA for use in treating adults with pancreatic adenocarcinoma. The investigational portion of this study is providing the chemotherapy drugs and radiation therapy before surgery. Primary Endpoint, R) resection rate ≥70%. Secondary Endpoints, Disease free survival, Overall survival , Perioperative mortality and morbidity.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2018-04-03; most recent amendment 2025-09-30.
Status change: Not Yet Recruiting → Recruiting 2019-07-29
Trial Details
NCT Number NCT03492671
Lead Sponsor Loma Linda University
Conditions Pancreas Adenocarcinoma, Resectable Pancreatic Cancer
Enrollment 30 participants
Start Date 2019-07-17
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-10-02